Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature
Saved in:
Main Authors: | Patricia Lopez, Sven Kohler, Seema Dimri |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Journal of Transplantation |
Online Access: | http://dx.doi.org/10.1155/2014/305931 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
by: Goran B. Klintmalm, et al.
Published: (2014-01-01) -
A Decade of Experience Using mTor Inhibitors in Liver Transplantation
by: Jeffrey Campsen, et al.
Published: (2011-01-01) -
mTOR Inhibitor Everolimus Modulates Tumor Growth in Small-Cell Carcinoma of the Ovary, Hypercalcemic Type and Augments the Drug Sensitivity of Cancer Cells to Cisplatin
by: Kewei Zheng, et al.
Published: (2024-12-01) -
Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
by: Gianluigi Zaza, et al.
Published: (2013-01-01) -
Absence of mTOR Inhibitor Effect on Hepatic Cyst Growth: A Case Report of a Kidney Transplant Recipient with Autosomal Dominant Polycystic Kidney Disease
by: L. Friedrich, et al.
Published: (2012-01-01)